Pharmacopeia Inc

Pharmacopeia — Pharmacopeia Drug Discovery — Investor Presentation (January 2007)

26 slides from Pharmacopeia's investor presentation, Jan 8, 2007

  1. Slide 1: Corporate Overview

    Slide 1: Corporate Overview

    Corporate Overview San Francisco January 2007 Discovering excellence, driving clinical success TM

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements . This presentation, and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which e

  3. Slide 3: Value Drivers - Balanced Risk

    Slide 3: Value Drivers - Balanced Risk

    Value Drivers - Balanced Risk Biopharmaceutical company Focused on cardiovascular and immunological diseases Leader in developing DARA – IND submitted 12/28/06 First-in-class dual-acting ARB and endothelin antagonists for kidney disease Deep pipeline of potential blockbusters 5 compounds in active c

  4. Slide 4: Balancing Risk to Build Value

    Slide 4: Balancing Risk to Build Value

    Balancing Risk to Build Value 8 Million Compound Library Largest in the Industry Integrated HTS Medicinal Chemistry Pharmacology Development GSK Wyeth Organon Cephalon Schering-Plough Bristol-Myers Squibb Unique Discovery Platform Strategic Partnerships Proprietary Programs High Value Portfolio Phar

  5. Slide 5: Agenda for Today

    Slide 5: Agenda for Today

    Agenda for Today Strong sustainable pipeline p38 kinase inhibitors approaching Phase 2 CXCR2 antagonist successfully completed Phase 1 DARA IND filed December 28th, 2006 – FIH planned in 1Q-07 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced di

  6. Slide 6: One of the Deepest Portfolios in Biotech

    Slide 6: One of the Deepest Portfolios in Biotech

    Angiogenesis a v b 3 / a v b 5 PS388023 Parkinson’s Adenosine A 2A PS246518 Rheumatoid/MS CCR1 PS375179 Derm/Ocular JAK3 Topical PS608504 Immuno/Inflam JAK3 PS608504 Inflammation PS873266 Respiratory PS948115 Metabolic Disease PS522501 Inflammation PS386113 Oncology PS241541 CNS PS778629 Cardiovascu

  7. Slide 7: Partnered Pipeline Advancing

    Slide 7: Partnered Pipeline Advancing

    Partnered Pipeline Advancing Partnered clinical programs advancing CXCR2 antagonist for COPD Successfully completed Phase 1 Active against biomarker at 50 mg in volunteers Continued clinical development on-going p38 kinase inhibitors for RA Approaching Phase 2 Well tolerated in multiple Phase 1 tria

  8. Slide 8: Agenda for Today

    Slide 8: Agenda for Today

    Agenda for Today Strong sustainable pipeline p38 kinase inhibitors approaching Phase 2 CXCR2 antagonist successfully completed Phase 1 DARA IND filed December 28th, 2006 – FIH planned in 1Q-07 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced di

  9. Slide 9: DARA – Dual Acting Angiotensin and Endothelin Receptor Antagonist

    Slide 9: DARA – Dual Acting Angiotensin and Endothelin Receptor Antagonist

    DARA – First-in-class DARA combines the properties of two marketed cardiovascular product classes in a single compound – Avapro and Tracleer Angiotensin II (Type 1) receptor blockers (ARBs) ETA selective endothelin receptor antagonists (ERAs) DARA’s combination of these activities has the potential

  10. Slide 10: Diabetic Kidney Disease – Medical Need

    Slide 10: Diabetic Kidney Disease – Medical Need

    Potentially control hypertension and fibrosis associated with loss of renal function pre- and post-transplant Diabetic Kidney Disease – Medical Need Progressive disease leading to dialysis and transplant 9 million diabetic nephropathy patients in the US 10 million in Japan and Europe $17B potential

  11. Slide 11: Resistant Hypertension – Medical Need

    Slide 11: Resistant Hypertension – Medical Need

    Worldwide in 2010 there are predicted to be 28 million patients with concomitant hypertension and diabetes Resistant Hypertension – Medical Need Hypertensives requiring 3 or more drugs to ‘control’ blood pressure ~10 million in US concomitantly receive 3 or 4 products classes 24% and 8% respectively

  12. Slide 12: ARB + ERA = Synergistic Combination

    Slide 12: ARB + ERA = Synergistic Combination

    Angiotensin II and Endothelin I Vasoconstriction Tissue proliferation and fibrosis Inflammation Preclinical Results Potent blockade of endothelin and angiotensin by oral route Potent BP lowering in predictive hypertension models (SHR and DOCA) Clinical Results – Diabetic nephropathy Improved renal h

  13. Slide 13: PS433540 – Potent as ARB and ERA

    Slide 13: PS433540 – Potent as ARB and ERA

    PS433540 – Potent as ARB and ERA PS-433540 (DARA) 1.4 > 10,000 BMS-19384 > 10,000 2 Irbesartan (Avapro) Endothelin IC 50 (nm, human) Angiotensin IC 50 (nm, human) Compound Irbesartan(Avapro®) AT 1 antagonist PS-433540 (DARA) AT 1 and ET A antagonist BMS-193884 ET A antagonist Angiotensin group Endot

  14. Slide 14: Angiotensin and Endothelin Blockade

    Slide 14: Angiotensin and Endothelin Blockade

    Angiotensin and Endothelin Blockade Angiotensin II PS433540 blocks both angiotensin and endothelin in vivo after oral administration in rodents with ED 50 = 0.9, 7.6 mpk ED 50 = 0.9 mg/kg Vehicle-adjusted % Inhibition (normalized) 0 10 20 30 40 50 60 70 80 90 100 Dose (mg/kg) 0.1 1.0 10.0 100.0

  15. Slide 15: PS433540 – Antihypertensive Activity

    Slide 15: PS433540 – Antihypertensive Activity

    PS433540 reduces blood pressure more than Irbesartan (Avapro) at 30 and 100 mmol/kg Effect of Irbesartan and PS433540 on Mean Arterial BP in Spontaneously Hypertensive Rats (SHR) PS433540 – Antihypertensive Activity PS433540

  16. Slide 16: Potential Treatment of Choice in Kidney Disease

    Slide 16: Potential Treatment of Choice in Kidney Disease

    Current Treatment of Renal Disease Unsatisfactory Disease progresses to dialysis and transplant despite treatment Impaired quality of life with high morbidity and mortality Emerging paradigm for better disease management ARBs approved for diabetic nephropathy Benefit demonstrated for investigational

  17. Slide 17: DARA Development Schedule

    Slide 17: DARA Development Schedule

    DARA Development Schedule Complete data and material transfer from BMS 2Q-06 Synthesis of 2 Kg GMP of active ingredient (API) 3Q-06 Pre-IND meeting with FDA 08/15/063Q-06 Submit IND 12/28/061Q-07 ‘First in man’ dosing 1Q-07 Initiate Phase 1b hypertension study End-07 Initiate Phase 2 2H-08

  18. Slide 18: Phase 1 Clinical Evaluation

    Slide 18: Phase 1 Clinical Evaluation

    Phase 1 Clinical Evaluation Phase 1a in Healthy Subjects Establish Safety SAD (Single Ascending Dose) – up to 7 dose levels MAD (Multiple Ascending Dose) – up to 4 dose levels Confirm Dual Activity Mechanism Angiotensin Challenge in Healthy Volunteers Endothelin Challenge in Healthy Volunteers Phase

  19. Slide 19: Agenda for Today

    Slide 19: Agenda for Today

    Agenda for Today Strong sustainable pipeline p38 kinase inhibitors approaching Phase 2 CXCR2 antagonist successfully completed Phase 1 DARA IND filed December 28th, 2006 – FIH planned in 1Q-07 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced di

  20. Slide 20: Strategic Partnerships

    Slide 20: Strategic Partnerships

    Strategic Partnerships Late stage optimization programs Upfront $15 million technology access fee Up to $35 million per program in milestones Double-digit royalties Builds portfolio and financial runway Pharmacopeia prosecutes Phase 1 and Phase 2 Non-dilutive tranched funding - $15 million Up to $83

  21. Slide 21: Strategic Partnerships – Wyeth JAK3 Alliance

    Slide 21: Strategic Partnerships – Wyeth JAK3 Alliance

    Strategic Partnerships Alliance to develop and commercialize JAK3 Inhibitors for Immunological and Inflammatory Diseases Upfront payment for discovery phase program - $5 million Up to $9MM in research funding over 3 years Up to $175MM in preclinical, clinical and commercialization milestones Double-

  22. Slide 22: Agenda for Today

    Slide 22: Agenda for Today

    Agenda for Today Strong sustainable pipeline p38 kinase inhibitors approaching Phase 2 CXCR2 antagonist successfully completed Phase 1 DARA IND filed December 28th, 2006 – FIH planned in 1Q-07 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced di

  23. Slide 23: Financial Summary

    Slide 23: Financial Summary

    Financial Summary For the 9 Months Ended September 30, 2006 $13.7 million in net revenue $19.6 million in net loss (including $2.0 million non-cash charge) Cash, Cash Equivalents and Marketable Securities $30.4 million as of December 31 st , 2005 $31.0 million as of September 30, 2006 Received $20 m

  24. Slide 24: Stock Information

    Slide 24: Stock Information

    Stock Information Stock Exchange: NASDAQ Stock Symbol: PCOP Shares Outstanding (10/31/2006): 21.1 million 52- Week Range: $3.39 - $6.51 Market Capitalization (01/04/2007): ~ $95 million Enterprise Value*: ~ $40 million *Calculated on cash and liquid investments as of 09/30/2006 and financing proceed

  25. Slide 25: Pharmacopeia Today

    Slide 25: Pharmacopeia Today

    Pharmacopeia Today DARA IND Submitted 12/28/06 First-in-class approach to significant markets Diabetic Nephropathy Resistant Hypertension Expect to be dosing healthy subjects in 1Q-07 Partnered clinical programs advancing CXCR2 antagonist for COPD – successfully completed Phase 1 (partnered with Sch

  26. Slide 26: Discovering excellence, driving clinical success

    Slide 26: Discovering excellence, driving clinical success

    Discovering excellence, driving clinical success TM

Source: SEC EDGAR · 8-K filed Jan 8, 2007

More decks from Pharmacopeia Inc